Astel­las hit with CRL for Claudin 18.2 drug due to third-par­ty man­u­fac­tur­ing is­sues

The FDA hand­ed Astel­las a com­plete re­sponse let­ter for its CLDN18.2 drug zol­be­tux­imab in gas­tric and gas­troe­sophageal junc­tion can­cers af­ter find­ing “un­re­solved de­fi­cien­cies” at a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER